CEO predicts fungal-based protein expression will be a 'CHO Stopper'

CHO platforms unsustainable for biopharma's future, says Dyadic

By Dan Stanton contact

- Last updated on GMT

The Chinese hamster's role in bioproduction is set to be challenged by alternative cell lines. Image: Istock/Madhourse
The Chinese hamster's role in bioproduction is set to be challenged by alternative cell lines. Image: Istock/Madhourse

Related tags: Cell culture

Industry is feeling the low yield and high cost limitations of the CHO cell line and must look to alternatives to make next-generation biological products, says fungal-based protein expression firm Dyadic International.

According to BioPlan Associates​’ 14thAnnual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, ​industry continues to favour mammalian cell lines to make biologics over novel-type expression systems like fungi, algae, and insect, opting in particular for CHO (Chinese hamster ovary) expression systems due to its “proven and safe nature (particularly in regulatory terms).”

But according to Mark Emalfarb, CEO and founder of Dyadic International, as biopharma looks to increase productivity for its multi-specific antibodies and biological vaccine pipelines, it will need to turn its back on the CHO cell line.

Genentech’s plasminogen activator Activase became the first human therapeutic product produced using CHO cells in 1987.

Since then the cell line has become an expression system of choice​ for biomanufacturers and is used to make best-selling monoclonal antibodies Rituxan, Humira and Enbrel, to name a few.

“Industry is starting to painfully experience the limitations of CHO expression yields for the next wave of biologics, bi-specific and tri-specific antibodies,”​ he told Biopharma-Reporter. “The already low yields and high cost of producing biologics with CHO appear to make CHO unsustainable and commercially unaffordable for producing these more complex molecules.”

High yielding, low-cost alternatives

Dyadic sold its industrial biotech business to DuPont for $75m in December 2015​ but retained the right to apply its C1 fungal expression system to human and animal biopharma applications.

The platform is based on Myceliopthora thermophila​ fungus and involves “straight forward”​ fermentation that can be scaled-up to various commercial levels with a purification process Emalfarb said is easier and less costly than with a CHO platform.

“CHO is likely the last cell line one would have chosen if the industry would have had the foresight to see the future 30 years ago,” ​he said, adding: “Our cell line data lead us to believe that our C1 cell line has a great potential to deliver what has been coined a ‘CHO Stopper.’​”

In the biofuel space, the platform has achieved production productivity of around 80 g/l of a single enzyme with high purity, and Dyadic hopes to bring the same success to biopharma.

“Abengoa, BASF, DuPont and others are utilising C1 to produce biofuel and other enzymes at up to 38 times the scale of [a typical biopharma stainless steel] 13,000 litre fermenter, in 50% or less the time, with 2-10 times the protein yield, with a fraction of the media cost and projected higher purity and simpler downstream processing,”​ Emalfarb said.

Industry shift

“There is a definite movement in place to find an alternative to CHO, and it is gaining momentum quickly,”​ Emalfarb told us.

Biogen, for example, said earlier this year​ it is looking at a “radical departure from the CHO platform”​ through research into fungal, algae and trypanosome systems.

And Dyadic itself has agreements with two undisclosed Big Pharma companies involving the expression of monoclonal antibodies through the C1 platform, and Emalfarb said there is interest from a number of other large multinationals engaged in therapeutics that have a high-dose regimen looking for a more cost-effective production cell line.

Obsolete capacity

The uptake of C1 and other hyper producing cell lines will disrupt the biomanufacturing infrastructure, Emalfarb warned, with recent investments made in commercial-scale mammalian cell culture capacity by CMOs – such as Samsung Biologics​ and Boehringer-Ingelheim​ – to become quickly outmoded.

“When C1 delivers on its promise in biopharma, as it did in industrial biotech… the tank infrastructure will choke [the biomanufacturers] and make their fermentation facilities and investment obsolete in the long run.”

The future of bioproduction is “not about more tanks and marginal competitive costs by scale, it's about high yielding cell lines,”​ he added.

Related news

Show more

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more